

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

DELAY IN DESPATCH OF 2021 ANNUAL REPORT

Reference is made to the announcement of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 11 April 2022 (the “**Announcement**”) in relation to the audited consolidated results of the Group for the year ended 31 December 2021 (the “**2021 Audited Final Results**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those used in the Announcement.

DELAY IN DESPATCH OF 2021 ANNUAL REPORT

Pursuant to Rule 13.46(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Company is required to despatch its annual report including its annual accounts for the year ended 31 December 2021 (the “**2021 Annual Report**”) to its shareholders not more than four months after the end of the financial year to which such annual accounts relate.

The Company has announced its 2021 Audited Final Results on 11 April 2022. As additional time is required to finalise the 2021 Annual Report, it is anticipated that the Company will not be able to despatch the 2021 Annual Report on or before 30 April 2022 in accordance with Rule 13.46(2)(a) of the Listing Rules. The Company expects to despatch the 2021 Annual Report to the shareholders of the Company on or before 13 May 2022 according to the “Frequently Asked Questions on the Joint Statement in relation to Results Announcement and Holding of General Meeting” issued by the Securities and Futures Commission of Hong Kong and the Stock Exchange and last updated on 8 April 2022. Further announcement(s) will be made by the Company as and when appropriate.

Shareholders and potential investors should exercise caution when dealing in shares of the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
29 April 2022

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.